Clinical Trial Update: Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009) [Phase 1]

View source ↗

Summary

Phase 1 trial update on extended administration of PEG-interferon alfa-2b in participants with solid tumors; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-07-15